source
- FDA grants three-month review extension for Exelixis' metastatic colorectal cancer candidateExelixis, a California drug developer, has provided the FDA with additional safety and efficacy data for its experimental therapy aimed at treating metastatic colorectal cancer. The agency respond…
- Novartis shareholder urges board overhaul after costly Avidity acquisition setbacksNovartis investor David Samra, managing director at Artisan Partners, told Reuters that the company’s board should be reshaped to improve oversight of its dealmaking activities. He said the board n…